These properties have prompted extensive research on PPARγin cancer treatment and prevention.Members of the thiazolidinedione (TZD) class of PPARγ agonists arecurrently approved for treatment of diabetes, and elicit many of the antitumorproperties of PPARγ activation through both PPARγ dependent and independentpathways [9–14]. Here, PPARG is linked to diabetes mellitus.